MHRAsafety guidance83% confidence
Guidance: Best practice guidance on patient information leaflets
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (prostate cancer) as Bayer.
Regulatory Analysis
This guidance sets out the legal framework for patient information leaflets as described in EU and national legislation and best practice in the area of information design.
Supporting Context
- Therapeutic area
- Oncology · Prostate Cancer
- Sub-indication
- Prostate Cancer
Related signal: Bayer's Study on ARPI Use in mHSPC Patients in Australia Aims to Inform Clinical Practice